Background We performed a multicenter, randomized open-label trial in patients with moderate to severe Covid-19 treated with a range of possible treatment regimens. Methods: Patients were randomly assigned to one of three regimen groups at a ratio of 1:1:1. The primary outcome of this study was admission to the intensive care unit. Secondary outcomes were intubation, in-hospital mortality, time to clinical recovery, and length of hospital stay (LOS). Between April 13 and August 9, 2020, a total of 336 patients were randomly assigned to receive one of the 3 treatment regimens including group I (hydroxychloroquine stat, prednisolone, azithromycin and naproxen; 120 patients), group II (hydroxychloroquine stat, azithromycin and naproxen; 116 patients), and group III (hydroxychloroquine and lopinavir/ritonavir (116 patients). The mean LOS in patients receiving prednisolone was 5.5 in the modified intention-to-treat (mITT) population and 4.4 days in the per-protocol (PP) population compared with 6.4 days (mITT population) and 5.8 days (PP population) in patients treated with Lopinavir/Ritonavir. Results The mean LOS was significantly lower in the mITT and PP populations who received prednisolone compared with populations treated with Lopinavir/Ritonavir (p = 0.028; p = 0.0007). We observed no significant differences in the number of deaths, ICU admission, and need for mechanical ventilation between the Modified ITT and per-protocol populations treated with prednisolone and Lopinavir/Ritonavir, although these outcomes were better in the arm treated with prednisolone. The time to clinical recovery was similar in the modified ITT and per-protocol populations treated with prednisolone, lopinavir/ritonavir, and azithromycin (P = 0.335; P = 0.055; p = 0.291; p = 0.098). Conclusion The results of the present study show that therapeutic regimen (regimen I) with low dose prednisolone was superior to other regimens in shortening the length of hospital stay in patients with moderate to severe COVID-19. The steroid sparing effect may be utilized to increase the effectiveness of corticosteroids in the management of diabetic patients by decreasing the dosage.
【저자키워드】 Corticosteroids, Low dose prednisolone, Anti-inflammatory drugs, 【초록키워드】 Corticosteroid, Corticosteroids, Low dose prednisolone, Lopinavir/ritonavir, Azithromycin, Trial, Open-label, Hydroxychloroquine, intensive care, severe COVID-19, mechanical ventilation, Lopinavir, Ritonavir, intensive care unit, intubation, outcome, Population, clinical recovery, Randomized, management, low dose, therapeutic, Patient, Effectiveness, ICU admission, naproxen, multicenter, group, Admission, patients, in-hospital mortality, diabetic patients, deaths, steroid, Hospital stay, Prednisolone, regimen, moderate to severe, open-label trial, number of deaths, LOS, Diabetic, Primary outcome, no significant differences, no significant difference, Secondary outcomes, dosage, mITT, mITT and PP populations, mITT population, Modified ITT, per-protocol populations, PP population, treatment regimens, treatment regimen, significantly lower, secondary, Randomly, modified intention-to-treat, diabetic patient, per-protocol population, Result, performed, receiving, treated, assigned, receive, ITT, patients treated, patients with moderate, per-protocol, 【제목키워드】 Efficacy, Corticosteroids, Trial, Open-label, Randomized, severe SARS-CoV-2, corticosteroids therapy, patients with moderate,